Shelton Earp

Shelton “Shelley” Earp, MD, is the Director of UNC Lineberger Comprehensive Cancer Center, Professor of Medicine & Pharmacology, Director of UNC Cancer Care, and Lineberger Professor of Cancer Research at UNC-Chapel Hill. Earp Lab is particularly interested in tyrosine-specific protein kinases in breast and prostate cancer, as well as lymphoma/leukemia.

MD
Distinguished Professor; Lineberger Professor of Cancer Research; Director, UNC Lineberger Comprehensive Cancer Center; Director, UNC Cancer Care
UNC-Chapel Hill
Cancer Cell Biology
Breast Cancer

Area of interest

In my role as Director I oversee the basic, translational, clinical and population science research at UNC Lineberger. My laboratory studies signal transduction in normal and neoplastic cells to determine new therapeutic options in a range of cancer including Breast, Lung, Pancreatic, Prostate Cancer as well as Leukemia s and melanoma. We have studied members of the EGF Receptor family for almost 40 years and identified several other tyrosine kinases including MerTK , a kinase that we are studying in the innate immune system as a target that leads to an immunosuppressive tumor micro-environment. To inhibit the action of MerTK we have teamed with Stephen Frye to create small molecule MerTK inhibitors that can reverse immunosuppression and enhance immunotherapy. This collaboration has resulted in a UNC start-up company. Meryx,Inc, which now has advanced a candidate to an FDA approved Phase 1 clinical trial in solid tumor patients at UNC and Emory. A trial in AML patients is anticipated next year

Find publications on PubMed

NC Reach profile